Simulations Plus, Inc.
1220 West Avenue J
Lancaster
California
93534
United States
Tel: 888-266-9294 US and Canada 661-723-7723<br>
Fax: 661-723-5524
Website: http://www.simulations-plus.com/
Email: info@simulations-plus.com
447 articles about Simulations Plus, Inc.
-
Simulations Plus to Present at Sidoti Fall Small Cap Investor Conference
9/14/2022
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at the Sidoti Fall Small Cap Investor Conference taking place virtually on September 21-22, 2022.
-
Simulations Plus to Present at Baird 2022 Global Healthcare Conference
9/7/2022
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at Baird’s 2022 Global Healthcare Conference taking place September 13-14, 2022, at the InterContinental New York Barclay Hotel.
-
Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease
8/31/2022
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released ILDsym™ version 1A, quantitative systems pharmacology (QSP) modeling software.
-
Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pKa)
8/4/2022
Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pK a ).
-
Simulations Plus Presented New Scientific Developments at PAGE 2022
7/26/2022
Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the presentation of five scientific posters by Simulations Plus scientists at the Population Approach Group in Europe (PAGE) conference held in Ljubljana, Slovenia.
-
Simulations Plus Realizes Early Success with its Concierge Program
7/14/2022
Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, recently invested in the creation of their Concierge Program, facilitating value-added strategic partnerships with customers through alliance management.
-
Simulations Plus Reports Third Quarter Fiscal 2022 Financial Results
7/6/2022
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its third quarter of fiscal 2022, ended May 31, 2022.
-
Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop
6/30/2022
Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop.
-
Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for COVID-19 Treatment
6/23/2022
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy.
-
Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call
6/21/2022
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the third quarter of fiscal year 2022, the period ended May 31, 2022, after the close of the financial markets on Wednesday, July 6, 2022.b
-
Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)
5/26/2022
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the release of version 10.4 (X.4) of its flagship machine learning modeling platform, ADMET Predictor ® .
-
U.S. FDA Renews Annual DILIsym Software Licenses for 2022
5/5/2022
Simulations Plus, Inc. (Nasdaq: SLP), today announced that the U.S. Food and Drug Administration (FDA) has renewed its licenses to the DILIsym® software platform, the DILIsym Services division’s flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI).
-
Simulations Plus Successfully Delivers FDA-Funded Project
4/28/2022
Simulations Plus, Inc. (Nasdaq: SLP), today announced the completion of a newly funded project from the U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG), through a collaboration of its Lixoft and Cognigen divisions, to establish the suitability of model-integrated evidence to demonstrate bioequivalence (BE) for long-acting injectable (LAI) and implantable drug products.
-
Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software
4/21/2022
Simulations Plus, Inc. today announced a new funded collaboration with a large pharmaceutical company to expand and validate the mechanistic in vitro dissolution models for intravitreal injectable formulations within the DDDPlus™ software.
-
Simulations Plus to Present at the Berenberg Discover AI Seminar
4/19/2022
Simulations Plus, Inc. today announced that management will be participating in the Berenberg Discover AI Seminar at The Newbury Boston in Boston, Massachusetts, on April 26, 2022.
-
Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software
3/29/2022
Simulations Plus, Inc. (Nasdaq: SLP), today announced that it has received a Phase II SBIR NIH grant for the further development and validation of its novel BIOLOGXsym™ platform, which is quantitative systems toxicology (QST) software focused on complex macromolecule liver safety.
-
Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference
3/24/2022
Simulations Plus, Inc. announced record-setting attendance and virtual content delivery for the 2022 MIDD+ Scientific Conference which was held February 16–17, 2022.
-
Simulations Plus to Present at Raymond James Institutional Investors Conference
3/2/2022
Simulations Plus, Inc today announced that management will be presenting at the Raymond James & Associates’ 43rd Annual Institutional Investors Conference, scheduled for March 6-9, 2022, at the JW Marriott Grande Lakes in Orlando, Florida.
-
Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2/8/2022
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be participating in BTIG’s MedTech, Digital Health, Life Science and Diagnostic Tools Conference, taking place virtually from February 15-17, 2022.
-
Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model
1/20/2022
Simulations Plus, Inc. (Nasdaq: SLP), today announced a new funded collaboration with a large pharmaceutical company to modify the GastroPlus® Advanced Compartmental Absorption and Transit (ACAT™) model in support of ongoing research programs for the treatment of gastrointestinal diseases.